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Complexes of muscarinic acetylcholine receptor and guanine nucleotide-binding protein (G protein) are formed in the presence of the agonist carba- 
chol. The complexes remain stable after removal of agonist, and survive subsequent solubilization from cardiac membranes and purification. Disso- 
ciation of the receptor from the G protein occurs when the antagonist atropine is added following removal of agonist. This is the first direct demon- 
stration ofdestabilization of reocptor-G protein complexes by the binding of an antagonist. 
Muscarinic acetylcholine receptor; G protein; Atropine 
1. INTRODUCTION 3. RESULTS 
It has been shown that agonists promote the forma- 
tion of stable complexes of muscarinic acetylchokc 
receptor (mAChR) and G protein in rat cardiac mem- 
branes [l]. Antagonists do not produce this effect. 
However, it is unclear whether receptor occupancy by 
antagonists is passive with regard to mAChR-G protein 
interaction. That is, can antagonists bind to a mAChR 
associated with a G protein and yet not disrupt the pro- 
tein-protein interaction? In this study, a method is 
presented to address this question. It is based on the 
ability to remove bound agonist from receptor with 
concentrations of GTP that do not disrupt the 
mAChR-G protein complex. With the ligand binding 
site unoccupied, effects of added antagonist on 
mAChR-G protein complex stability can be monitored. 
2. MATERIALS AND METHODS 
Rat hearts were obtained from Pet Freezeand membranes prepared 
as described [I 1. Membranes were resuspended in 10 mM Tris, I mM 
EDTA, 3 mM MgClz and incubated with 100 nM carbachol (Sigma) 
for 30 min at 4°C. GTP (0.1 mM) was added where indicated and 
samples incubated for an additional 10 min at 4% Samples were then 
diluted IO-fold with 10 mM Tris, I mM EDTA in the presence or 
absence of 10 PM atropine (Sigma) and membranes collected by cen- 
trifugefion. Solubilization of mAChRs, purification by wheat germ 
agglutinin chromatography, immunoprecipitation using 31-ID1 anti- 
receptor antibody [2,3], and Western blotting wcrc as described 
previously [I]. [‘H]NMS (Amcrshnm) and (“H]oxo-M (DuPont/ 
NEN) binding to hcart membranes was pcrfornred as descrihcd [I). 
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The monoclonal antibody, 31-lD1, used in this study 
quantitatively (> 9Ocr/o) precipitates muscarinic recep- 
tors solubilized from porcine or rat heart [2,3], or from 
cells transfected with cDNA coding for the m2 
muscarinic receptor (B.B. Wolfe, personal communica- 
tion), When cardiac membranes are incubated with car- 
bachol to activate mAChRs, this antibody can be used 
to precipitate solubilized muscarinic receptors and 
associated G proteins [I]. G proteins present in the im- 
munoprecipitated complexes are identified by Western 
blotting using antibodies specific for G protein alpha 
subunits [4]. It was previously shown [l] that low con- 
centrations of GTP (0.1 mM) could fully reverse 
agonist binding to membrane-bound mAChRs, but did 
not reverse the mAChR-G protein interaction, This 
observation forms the basis of the current experiments. 
Formation of stable mAChR-G protein complexes 
was produced by incubation of cardiac membranes with 
the agonist carbachol (100 nM). Agonist was then 
removed from the complex using a limiting concentra- 
tion of GTP (0.1 mM), followed by centrifugation and 
resuspension of membranes in buffer lacking agonist or 
GTP. To confirm the removal of agonist, [3H]NMS 
binding was indistinguishable using membranes treated 
with carbachol, followed by 0,l mM GTP (Fig. 1B). or 
control membranes not initially exposed to agonist and 
GTP (Fig. 1A). [3H]NMS binding was inhibited by ap- 
proximately 50% when 100 nM carbachol was included 
in the binding assay (not shown). A comparison of 
[3H]oxo-M binding to control (Fig. 1A) or treated (Fig. 
1B) membranes suggests that the GTP concentration is 
reduced under these conditions to levels which do not 
interfere with high-affinity agonist binding. 
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1 2 3 4 5 6 Fig. 1. Binding of [‘HINMS and [‘HJOxo-M SC cardiac membrane:. 
(A) control membranes; (B) membranes incubated with 100 i&l ‘car- 
bachol, followed by 0.1 mM GTP. Radioligands were added after 
ccntrifugation of membranes and resuspension in buffer lacking car- 
bachol or GTP. Binding of radioligands (mean -C SEM, n = 3) in the 
presence n or absence q of I JAI atropine. 
Detection of the mAChR-G protein complexes 
formed under these experimental conditions is shown in 
Fig. 2. Thus, lane 2 in Fig. 2 shows Ga subunits that co- 
purified with mACh receptors incubated with car- 
bachol. No Ga subunits were detected when atropine 
alone was used (lane 6). When membranes were 
incubated with agonist to induce formation of 
mAChR-G protein complexes, and the agonist remov- 
ed by addition of 0.1 mM GTP, the mAChR-G protein 
complexes initially formed remained present (lane 3). 
However, if the antagonist atropine (10 PM) was added 
during (not shown) or subsequent to incubation with 
GTP, the levels of mAChR-G protein complex were 
reduced to background levels (lane 4). If atropine was 
added to carbachol-treated samples without incubation 
with GTP, no reduction in the levels of mAChR-G pro- 
tein complex was observed (lane 5). These results sug- 
gest that the mAChR ligand binding site must be cleared 
of bound agonist before atropine can bind to and 
destabilize the mAChR-G protein complex. These 
results also confirm the ligand binding experiments 
(Fig. 1) showing that the agonist was removed by in- 
cubation with GTP. 
The above experiments demonstrated.the ability of 
atropine to destabilize mAChR-G protein complexes in 
the absence of agonist. This effect of atropine was also 
observed in the presence of agonist when GTP (0.1 mM) 
was incluced in the incubation. In these experiments, 
membranes were incubated with a concentration of 
atropine (10 nM) sufficient to saturate all receptors, 
based on 100% inhibition of [‘H]NMS binding (not 
shown), At the same concentration of NMS, 10 PM car- 
bachol produced full occupancy of high-affinity agonist 
binding sites (Fig. 3A and B), Under these conditions, 
the high-affinity agonist binding was reversed by addi- 
tion of 0. I mM GTP (Fig. 3). In membranes incubated 
Fig. 2. Reversal of mAChR-G protein complexes by atropine. 
Western blot shows GU subunits that co-purified with mAChRs 
solubilized from cardiac membranes treated as indicated above each 
lane. Lane 1 shows Ga subunits partially purified from rat brain [I]. 
Resolution of G,d I and G,39 subunits is not achieved under these con- 
ditions. Carb = 100 nM carbachol: Atr = 10 uM atropine; GTP = 
0.1 mM. 
I 4000 r 
3200 
E 
ii 2400 
In 
z 
1600 
800 
0 
A 
1 
NTROL TP + CARE t 
+GTP 
1000 - 
Fig. 3. A. Mcmbrancs were incubntcd for 30 min on ice with IO nM 
IJHJNMS plus 10 FM cnrbachol or 0.1 mM GTP whcrc indicated. o 
total binding; l plus 1 PM atropinc (mean f SEM, u = 3). B. Mcm- 
brancs wcrc incubated with 10 nM ['HJNMS plus various conccntra- 
tions of carbnchol for 30 min on ice. Points arc the avcragc of 
duplicate dctcrminations. 
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Fig. 4. Reversal of mAChR-G protein complexes by atropine in the 
presence of agonist. Western blot shows Ga subunits that co-purified 
with mAChRs treated as indicated above each lane. Garb= 100 nM 
carbachol; Atr = 10 PM atropine; GTP = 0.1 mM. 
under identical experimental conditions (Fig. 4), car- 
bachol alone (10 PM) or in the presence of 10 nM 
atropine supported mAChR-G protein interaction 
(lanes 2 and 4). GTP alone did z\)t reverse this effect of 
carbachol (lane 5). In contrast, in the presence of 10 nM 
atropine in addition to carbachol and GTP, no 
mAChR-G protein complexes were detected (lane 6). 
4. DISCUSSION 
The ability of mAChR agonists to promote forma- 
tion of mAChR-G protein complexes in cardiac mem- 
branes has been described previously ill, and docu- 
mented again in this report. The complexes thus formed 
are refractory to additions of low concentrations of 
GTP and GDP which are sufficient to remove bound 
agonist, and therefore do not appear to require the con- 
tinuing presence of agonist for the proteins to remain in 
association. We now document that the muscarinic an- 
tagonist atropine dissociates complexes of mAChR and 
G protein initially induced by agonist. Regarding the ef- 
fects of GTP on muscarinic agonist binding, and the use 
of this parameter as an index of receptor-G protein in- 
teraction, we have found that low (10 and 100 nM) con- 
centrations of carbachol or [3H]oxo-M support levels of 
mAChR-G protein complex formation which are 
equivalent in the presence or absence of 0.1 mM GTP. 
Using direct binding of [3H]oxo-M or competition of 
carbachoi for [3H]NMS binding to cardiac membranes, 
it can be shown that this same concentration of GTP 
fully inhibits high-affinity agonist binding to the 
muscarinic receptor [l]. In the case of the competition 
binding experiments, and depending on the levels of 
[3H]-antagonist used as a tracer, complexes of 
mAChR-G protein formed by carbachol under these 
conditions appear to be reversed by binding of an- 
tagonist present during the incubation. Thus, using 
radiolabelled agonist, no inference could be made 
about the effect of GTP on the presence or absence of 
mAChR-G protein complexes, while competition bind- 
ing using high concentrations of radiolabelled an- 
tagonist would provide a more accurate estimate of the 
existence of R-G complexes. 
In summary, this report documents the reversal of 
muscarinic receptor-G protein complexes by antagonist 
binding. Further studies using this approach will clarify 
other parameters associated with this protein-protein 
interaction. 
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